Parallax Volatility Advisers
DNA icon

Parallax Volatility Advisers’s Ginkgo Bioworks DNA Stock Holding History

Parallax Volatility Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-503
Closed -$167K – 2806
2021
Q4 		$167K Buy
+503
New +$239K ﹤0.01% 1681

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Parallax Volatility Advisers's DNA Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 2,496 shares — an estimated $186K sold.

Parallax Volatility Advisers first reported a position in DNA in Q4 2021 and held it in 4 quarters. The position peaked at $251K in Q4 2021. 349 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

  • Parallax Volatility Advisers reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,496 Ginkgo Bioworks shares in Q3 2023, an estimated $186K.
  • Parallax Volatility Advisers first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 4 quarters.
  • Parallax Volatility Advisers's Ginkgo Bioworks position peaked at $251K in Q4 2021.
  • 349 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.